Company Filing History:
Years Active: 2015
Title: The Innovative Contributions of Perry Peters
Introduction
Perry Peters is a notable inventor based in San Diego, CA. He has made significant strides in the field of psychopharmacology, particularly with his innovative approach to treating psychosis. His work has the potential to improve the quality of life for many individuals suffering from mental health disorders.
Latest Patents
Perry Peters holds a patent for a groundbreaking combination of pimavanserin and risperidone for the treatment of psychosis. This patent highlights the effectiveness of combining 5-HT2A inverse agonists or antagonists, such as pimavanserin, with antipsychotics like risperidone. The combination is shown to induce a rapid onset of antipsychotic action and increase the number of responders compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. Additionally, the combinations are effective at decreasing the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic.
Career Highlights
Perry Peters is associated with Acadia Pharmaceuticals Inc., where he continues to contribute to the advancement of psychiatric treatments. His innovative work has garnered attention in the pharmaceutical industry, showcasing his commitment to improving mental health therapies.
Collaborations
Perry has collaborated with notable colleagues, including David Furlano and Daun Bahr, to further enhance the research and development of effective treatments for psychosis.
Conclusion
Perry Peters is a distinguished inventor whose work in combining pimavanserin and risperidone represents a significant advancement in the treatment of psychosis. His contributions have the potential to transform the landscape of mental health treatment, making a lasting impact on patient care.